ARTICLE | Deals
Kriya rolls up Redpin, adds neurology to its gene therapy scope
In second M&A deal this year, Patient Square-backed Kriya adds epilepsy, trigeminal neuralgia programs along with platform in ‘nine-digit’ acquisition
November 16, 2022 7:37 PM UTC
Well-funded Kriya’s purchase of Redpin, its second acquisition of 2022, will broaden its gene therapy pipeline to include a new therapeutic area: neurological disorders.
The deal gives Kriya Therapeutics Inc. a chemogenetics platform and two preclinical lead programs from Redpin Therapeutics Inc.: one to treat epilepsy, and one for trigeminal neuralgia. A source with knowledge of the deal’s price described it as a nine-digit sum, but declined to provide further details...